🚀 VC round data is live in beta, check it out!
Ventyx Biosciences Valuation Multiples
Discover revenue and EBITDA valuation multiples for Ventyx Biosciences and similar public comparables like Philogen, HK inno.N, Pacira BioSciences, Kaken Pharmaceutical and more.
Ventyx Biosciences Overview
About Ventyx Biosciences
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
Founded
2018
HQ
Employees
82
Website
Financials (FY)
EV
$822M
Ventyx Biosciences Stock Performance
Ventyx Biosciences has current market cap of $1B, and enterprise value of $822M.
Market Cap Evolution
Ventyx Biosciences' stock price is $14.00.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $822M | $1B | 0.0% | XXX | XXX | XXX | — |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialVentyx Biosciences Valuation Multiples
Ventyx Biosciences Financial Valuation Multiples
As of April 19, 2026, Ventyx Biosciences has market cap of $1B and EV of $822M.
Equity research analysts estimate Ventyx Biosciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $822M | XXX | $822M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Ventyx Biosciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Ventyx Biosciences Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Ventyx Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Philogen | XXX | XXX | XXX | XXX | XXX | XXX |
| HK inno.N | XXX | XXX | XXX | XXX | XXX | XXX |
| Pacira BioSciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Kaken Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Strides Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ventyx Biosciences M&A Activity
Ventyx Biosciences acquired XXX companies to date.
Last acquisition by Ventyx Biosciences was on XXXXXXXX, XXXXX. Ventyx Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Ventyx Biosciences
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialVentyx Biosciences Investment Activity
Ventyx Biosciences invested in XXX companies to date.
Ventyx Biosciences made its latest investment on XXXXXXXX, XXXXX. Ventyx Biosciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Ventyx Biosciences
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Ventyx Biosciences
| When was Ventyx Biosciences founded? | Ventyx Biosciences was founded in 2018. |
| Where is Ventyx Biosciences headquartered? | Ventyx Biosciences is headquartered in United States. |
| How many employees does Ventyx Biosciences have? | As of today, Ventyx Biosciences has over 82 employees. |
| Who is the CEO of Ventyx Biosciences? | Ventyx Biosciences' CEO is Raju S. Mohan. |
| Is Ventyx Biosciences publicly listed? | Yes, Ventyx Biosciences is a public company listed on Nasdaq. |
| What is the stock symbol of Ventyx Biosciences? | Ventyx Biosciences trades under VTYX ticker. |
| When did Ventyx Biosciences go public? | Ventyx Biosciences went public in 2021. |
| Who are competitors of Ventyx Biosciences? | Ventyx Biosciences main competitors are Philogen, HK inno.N, Pacira BioSciences, Kaken Pharmaceutical. |
| What is the current market cap of Ventyx Biosciences? | Ventyx Biosciences' current market cap is $1B. |
| Is Ventyx Biosciences profitable? | No, Ventyx Biosciences is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.